NL-OMON21527CompletedNot Applicable
A Phase II study to investigate the effect of Glivec® (imatinib mesylate, formerly known as STI571) in patients with inoperable medullary thyroid carcinoma.
/A0 sites15 target enrollmentStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 15
Study Overview
Brief Summary
de Groot JW, Zonnenberg BA, van Ufford-Mannesse PQ, de Vries MM, Links TP, Lips CJ, Voest EE.A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma.J Clin Endocrinol Metab. 2007 Sep;92(9):3466-9.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •1. Patients „d 18 years of age;
- •2. The subject has advanced histologically proven medullary thyroid cancer. Advanced disease is defined as locally recurrent disease or metastatic disease that is not amenable to curative resection. The subject must have measurable disease;
Exclusion Criteria
- •1. The subject is < 5 years free of another primary malignancy except: if the other primary malignancy is not currently clinically significant nor requiring active intervention, or if the other primary malignancy is a basal cell skin cancer or a cervical carcinoma in situ;
- •2. The subject with known brain metastases;
Investigators
Similar Trials
Active, not recruiting
Not Applicable
A clinical study evaluating the efficacy of topical cromoglicate solution compared to placeboin the treatment of mastocytosisMedDRA version: 15.0Level: PTClassification code 10012812Term: Diffuse cutaneous mastocytosisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 15.0Level: LLTClassification code 10056452Term: Indolent systemic mastocytosisSystem Organ Class: 10005329 - Blood and lymphatic system disordersmastocytosisEUCTR2011-006275-20-DEEO Pharma A/S
Recruiting
Phase 1
TOPOLOGY : A phase II study to evaluate the efficacy and toxicities of PLX038, in patients with locally advanced or metastatic triple-negative breast cancerAdvanced or metastatic triple-negative breast cancerMedDRA version: 23.0Level: LLTClassification code: 10084066Term: Triple negative breast cancer metastatic Class: 10029104CTIS2022-501507-27-00Institut Curie44
Not yet recruiting
Not Applicable
Phase II study on the feasibility and efficacy of consolidation with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma having achieved partial or complete remission after induction with R-PECC chemotherapy.Aggressive B-cell NHL: FL grade 3b and DLBCNL-OMON24909Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON) P/a HOVON Data CenterErasmus MC - Daniel den HoedPostbus 52013008 AE RotterdamTel: 010 4391568Fax: 010 4391028e-mail: hdc@erasmusmc.nl60
Recruiting
Not Applicable
Phase II study on the feasibility and efficacy of R-DHAP + HD-MTX, combined with intrathecal rituximab, followed by autologous stem cell transplantation in patients with a recurrent aggressive B-cell lymphoma with CNS localisation.Recurrent aggressive B-cell lymphoma with CNS localisation, DLBCL, non-hodgkin lymphoma, NHNL-OMON23427Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON) P/a HOVON Data CenterErasmus MC - Daniel den HoedPostbus 52013008 AE RotterdamTel: 010 7041560Fax: 010 7041028e-mail: hdc@erasmusmc.nl35
Active, not recruiting
Not Applicable
Phase II multicentric study to evaluate the efficacy and the safety of Bendamustine in adjunct to Etoposide, Aracytabin and Melphalan (BeEAM) as a preparative regimen for autologous stem cell transplantation in refractory/relapsed lymphoma patients. - BeEAMDiagnosis of Non-Hodgkin lymphoma of any subtype, chronic lymphocytic leukemia, or Hodgkin disease either refractory or relapsed after at least one line of chemotherapy.MedDRA version: 9.1Level: HLGTClassification code 10025320MedDRA version: 9.1Level: HLGTClassification code 10025319EUCTR2008-002736-15-ITAZIENDA OSPEDALIERA OSPEDALE S. SALVATORE